SuperworthFennec Pharmaceuticals profit margin FENC
Gross, operating and net profit as a share of revenue over the last twelve months, from 2023.
- Net margin, 12 months
- −5.5%
- Operating margin, 12 months
- −1.9%
- Net margin on a year earlier
- +30.7 pts
- Peer median
- 21.7%
Over the twelve months to Jun 30, 2026, Fennec Pharmaceuticals kept −5.5% of its revenue as net profit, with an operating margin of −1.9%.
The median for 4 biotech stocks of a similar size is 21.7%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −21.8% | −14.1% | n/a |
| FY2024 | −0.9% | 5.4% | n/a |
| FY2023 | −75.5% | −60.1% | 94.1% |
| FY2022 | n/a | n/a | n/a |
| FY2021 | n/a | n/a | n/a |
| FY2020 | n/a | n/a | n/a |
| FY2019 | n/a | n/a | n/a |
| FY2018 | n/a | n/a | n/a |
| FY2017 | n/a | n/a | n/a |
| FY2016 | n/a | n/a | n/a |
| FY2015 | n/a | n/a | n/a |
| FY2014 | n/a | n/a | n/a |
| FY2013 | n/a | n/a | n/a |
| FY2012 | n/a | n/a | n/a |
| FY2011 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −5.5% | +30.7 pts | −1.9% | |
| Q1 FY26 | −16.4% | +30.3 pts | −11.0% | |
| Q4 FY25 | −21.8% | −20.9 pts | −14.1% | |
| Q3 FY25 | −17.9% | −15.6 pts | −12.0% | |
| Q2 FY25 | −36.1% | −41.7 pts | −29.1% | |
| Q1 FY25 | −46.7% | −53.0 pts | −38.8% | |
| Q4 FY24 | −0.9% | +74.6 pts | 5.4% | |
| Q3 FY24 | −2.3% | n/a | 3.4% | |
| Q2 FY24 | 5.6% | n/a | 12.0% | |
| Q1 FY24 | 6.3% | n/a | 13.9% | |
| Q4 FY23 | −75.5% | n/a | −60.1% | |
| Q3 FY23 | n/a | n/a | n/a |
Against its peers
Companies in Biotechnology nearest Fennec Pharmaceuticals' size, closest first, today.
| Company | Profit margin |
|---|---|
| FENCFennec Pharmaceuticals | −5.5% |
| PLXProtalix BioTherapeutics | 23.5% |
| MGTXMeiraGTx | 19.9% |
| VCELVericel | 7.9% |
| ADMAAdma Biologics | 33.0% |
| Peer median | 21.7% |
Where Fennec Pharmaceuticals ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Fennec Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.